Close
Novotech
Jabsco PureFlo 21 Single Use

Klöckner Pentaplast acquires the packaging company from Farmamak Review Initiative

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Structural Pricing Pressure is Reshaping Pharma in 2026

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.

Merck Targets $70B Revenue in 2026 with Cidara Deal

Merck’s roughly $9.2 billion acquisition of Cidara Therapeutics and its $70 billion revenue ambition mark a strategic pivot toward respiratory vaccines and antivirals. Explore how this deal reshapes Merck’s portfolio and signals a broader industry shift toward targeted M&A to offset patent cliffs.

U.S. Drug Pricing Reset Becomes Real in 2026

In 2026, U.S. drug pricing finally moved from policy debate to P&L impact. The first set of Medicare “maximum fair prices” and Most‑Favoured‑Nation–style reference pricing are reshaping pharma margins and launch strategies.
- Advertisement -

The global rigid film producer Klöckner Pentaplast will acquire Farmamak Review from Venture Capital Investment Trust Inc. (Review Initiative). Farmamak will operat on as a subsidiary within the Klöckner Pentaplast Group. 

Klöckner Pentaplast, a world-leading producer of rigid films for the pharmaceutical, medical devices, food and consumer packaging and beverages, has signed a definitive agreement to acquire the rigid film producer Farmamak. Farmamak is a leading rigid film producer in Turkey (and the surrounding regions) and you currently resides under Review Initiative. 

“We are excited for our first acquisition since 2011, together – with Farmamak as a local leader – this transaction comments found us to improve our customer focus in Turkey and throughout the Middle East to improve our regional service and capabilities, “commented Wayne M. Hewett, Chief Executive Officer, Klöckner Pentaplast. 

” Always a pioneer and innovator in its field, Farmamak Introduced many industry firsts and Achieved sustainable growth over a number of years. I am sure that under the ownership of Klöckner Pentaplast, the business will further build on this solid heritage and see further growth, “explained Review Initiative CEO Mustafa Aydemir. 

Farmamak, with sales of £ 155 million (~ EUR 47 million), employs around 230 people and its production site is located in Gebze, Turkey. “Integrating Farmamak into the Klöckner Pentaplast Group shows great confidence in the potential of our company and our employees and brings more opportunities in the market to unlock further growth” said Kurt Kuruç, Managing Director of Farmamak. 

Through targeted portfolio adjustments, Farmamak AiMS to further strengthened its position as a leading film provider in the food, consumer packaged goods and pharmaceutical segments. Together with Klöckner Pentaplast, Farmamak offers a wider range of products and Comprehensive services at a local level. 

the transaction is subject to approval by the competition Authorities. until such approval is granted, the operator will Klöckner Pentaplast and Farmamak independently. 

About Gözde Girişim
Gözde Girişim is a listed private equity company, established to invest in companies having financial and operational restructuring needs and growth potential. Gözde Girişim targets to invest in non-food companies having financial and operational restructuring needs which promise comparably rapid and higher returns. It is principle for Gözde Girişim to benefit from the strategic advantages, know-how and expert resources of Yıldız Holding developed over many years.

About Klöckner Pentaplast
The Klöckner Pentaplast Group is a global leader in providing packaging, printing, and specialty solutions serving the pharmaceutical, medical device, food, beverage, and card markets, among others. With a broad portfolio of rigid plastic films and services powered by innovation, Klöckner Pentaplast plays an integral role in the customer value chain by marketing and protecting product integrity, safety, consumer health, and, ultimately, brand reputation. Klöckner Pentaplast has operations in 12 countries with 18 production sites. Within the last fiscal year, the company had sales of € 1.284 billion and currently employs over 3,200 people committed to serving customers worldwide. The Klöckner Pentaplast Group is wholly owned by an investor group led by SVP Global.

 

 

Latest stories

Related stories

Structural Pricing Pressure is Reshaping Pharma in 2026

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.

Merck Targets $70B Revenue in 2026 with Cidara Deal

Merck’s roughly $9.2 billion acquisition of Cidara Therapeutics and its $70 billion revenue ambition mark a strategic pivot toward respiratory vaccines and antivirals. Explore how this deal reshapes Merck’s portfolio and signals a broader industry shift toward targeted M&A to offset patent cliffs.

U.S. Drug Pricing Reset Becomes Real in 2026

In 2026, U.S. drug pricing finally moved from policy debate to P&L impact. The first set of Medicare “maximum fair prices” and Most‑Favoured‑Nation–style reference pricing are reshaping pharma margins and launch strategies.

White House-Big Pharma Tariff and Pricing Deals in 2026

In early 2026, the White House struck a series of tariff and pricing deals with major pharma firms, linking lower prices for GLP‑1 and other drugs to tariff relief and new distribution channels. Explore how these arrangements are reshaping U.S. pharma pricing, access and global spillovers.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »